EUVIMEDEUVIMED entdecken
Crossref

Discovery of Potent and Selective Pyrrolo[2,3- d ]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations

Zhenhua Wu, Xueyan Liu, Xiao-E Yan, Xinyu Wu, Wei Huang, Jiajia Li, Yuanming Xiu, Cairui Lv, Chi Sun, Zheng Wang, Gaoke Xu, Xiaobing Wu und 7 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhenhua Wu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, Ch…. Hauptthemen laut MEDLINE: ErbB Receptors, Pyrimidines, Protein Kinase Inhibitors, Pyrroles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xiamen Southern Oceanographic Center, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown clinical efficacy in nonsmall cell lung cancer (NSCLC), but acquired resistance mutations─especially the cis-EGFRT790M/C797S─remain a major challenge. Here, we report the identification of a series of pyrrolo[2,3-d]pyrimidine derivatives that inhibit C797S-mediated EGFR triple mutants. Among them, compound 31r shows subnanomolar IC50 values against Ba/F3 EGFR19del/T790M/C797S and Ba/F3 EGFRL858R/T790M/C797S, while sparing wild-type EGFR. Its binding mode with EGFR19del/T790M/C797S was revealed by a cocrystal structure, providing structural insights into its potency and selectivity. Compound 31r also displays excellent kinome selectivity and drug-like properties, including good metabolic stability (T1/2 = 5.9 h) and oral bioavailability (F = 24%). Most importantly, 31r significantly suppressed tumor growth in PC-9 EGFR19del/T790M/C797S xenograft models, achieving regression at 80 mg/kg once daily. These results highlight 31r as a promising lead compound for overcoming resistance associated with third-generation EGFR-TKIs and support its further development for drug-resistant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsPyrimidinesProtein Kinase InhibitorsPyrrolesAntineoplastic AgentsHumansAnimalsMutationStructure-Activity RelationshipCell Line, TumorMiceDrug DiscoveryCarcinoma, Non-Small-Cell LungCell ProliferationLung NeoplasmsMice, NudeXenograft Model Antitumor AssaysRats

Substanzen

ErbB ReceptorsPyrimidinesProtein Kinase InhibitorsPyrrolesAntineoplastic AgentsEGFR protein, humanPyrrolo(2,3-d)pyrimidine

Autor:innen und Institutionen

  • State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, China.
  • State-Province Joint Engineering Laboratory of Targeted Drugs from Natural Products, Xiamen University, Xiamen 361102, China.
  • RedCloud Bio Co., Ltd., Taizhou 225326, China.
  • Institute of Translational Medicine, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Department of Biophysics, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
  • Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen University, Xiamen 361003, China.

ORCID-Profile: Jianming Zhang, Xianming Deng

Förderung

  • National Natural Science Foundation of China
  • Xiamen Southern Oceanographic Center
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • Higher Education Discipline Innovation Project
  • New Cornerstone Science Foundation

Zitieren

APA

Wu, Z., Liu, X., Yan, X. E., Wu, X., Huang, W., Li, J., Xiu, Y., Lv, C., Sun, C., Wang, Z., Xu, G., Wu, X., Hu, Z., Huang, H., Huang, X., Zhang, J., Yun, C. H., Li, L., & Deng, X. (2025). Discovery of Potent and Selective Pyrrolo[2,3- d ]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01320

Vancouver

Wu Z, Liu X, Yan XE, Wu X, Huang W, Li J, et al. Discovery of Potent and Selective Pyrrolo[2,3- d ]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01320

BibTeX
@article{Wu2025,
  author = {Wu, Zhenhua and Liu, Xueyan and Yan, Xiao-E and Wu, Xinyu and Huang, Wei and Li, Jiajia and Xiu, Yuanming and Lv, Cairui and Sun, Chi and Wang, Zheng and Xu, Gaoke and Wu, Xiaobing and Hu, Zhiyu and Huang, Huiying and Huang, Xin and Zhang, Jianming and Yun, Cai-Hong and Li, Li and Deng, Xianming},
  title = {Discovery of Potent and Selective Pyrrolo[2,3- d ]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01320}
}
Kostenlos starten →